	US 12,290,527 B2
	Compositions and methods for reducing major thrombotic events in cancer patients
Jeffrey I. Zwicker, Boston, MA (US); Bruce Furie, Boston, MA (US); Jack Davis Stopa, Boston, MA (US); and Robert Flaumenhaft, Boston, MA (US)
Assigned to BETH ISRAEL DEACONESS MEDICAL CENTER, INC., Boston, MA (US)
Filed by Beth Israel Deaconess Medical Center, Inc., Boston, MA (US)
Filed on Jan. 12, 2024, as Appl. No. 18/412,414.
Application 18/412,414 is a continuation of application No. 16/696,280, filed on Nov. 26, 2019, granted, now 11,872,241.
Claims priority of provisional application 62/773,696, filed on Nov. 30, 2018.
Prior Publication US 2024/0285659 A1, Aug. 29, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7048 (2006.01); A61K 31/352 (2006.01); A61K 31/375 (2006.01); A61K 31/45 (2006.01); A61K 31/519 (2006.01); A61P 35/04 (2006.01)

CPC A61K 31/7048 (2013.01) [A61K 31/352 (2013.01); A61K 31/375 (2013.01); A61K 31/45 (2013.01); A61K 31/519 (2013.01); A61P 35/04 (2018.01)]

16 Claims

1. A method for reducing or preventing formation of a thrombus in a patient with cancer at increased risk for bleeding, with an elevated level of soluble P-selectin when compared to a reference or baseline level of soluble P-selectin, comprising administering to the patient a composition comprising an effective amount of isoquercetin, vitamin B3, and vitamin C, the effective amount of isoquercetin being about 500 mg per day,

comprising administrating the composition to the patient for a period of at least about 2 months;

wherein the patient does not exhibit primary venous thromboembolism after administration of the composition.